In 2025, OccamzRazor expanded its collaborations with Boehringer Ingelheim (BI) and Leiden University Medical Center (LUMC), reinforcing both its commercial traction and scientific credibility. The BI partnership progressed into a new phase focused on model validation and production integration, while the LUMC collaboration secured continued funding, formalized IP rights, and led to the company’s first peer-reviewed publication (npj Parkinson’s Disease) within the ProPark consortium.

 

Over the year, OccamzRazor strengthened its data platform and broadened its clinical collaborations, embedding its AI capabilities deeper into high-value research environments and positioning itself as a trusted analytical partner.

 

The next challenge is converting strong pilot results into scalable, recurring deployment within complex biotech workflows. As validation advances and partnerships mature, OccamzRazor is steadily transitioning from proof of concept to durable integration.